STARTUP PROFILE

Coherence Neuro

COUNTRY
UK
FOUNDED
2022
CATEGORY
Neuromodulation
Implementing precision bioelectronic therapy with SOMA-1, an implant during glioblastoma surgery that continuously monitors and disrupts tumor-driving electrical signals.
Visit website →
Market Notes · Biweekly

Track this company

Funding, launches and regulatory moves across the neurotech startup map.

Subscribed. Check your inbox to confirm.

•
Neurofounders Insights
$   Funding   -
Series A
MODALITY
Others
FORM FACTOR
Implant
INTERFACE DEPTH
Implantable
INDICATION
Tumors
TARGET USER
Patients
REGULATORY STAGE
Investigational
Coherence Neuro sits at the intersection of oncology and neurotechnology, using bioelectronic implants to modulate tumor-associated electrical activity in glioblastoma. This is a highly novel approach with limited precedent, placing it in a high-risk, high-reward translational category.
•
Mentioned in Market Notes
MOST RECENT COVERAGE
#
12
NVIDIA and OpenAI invest in neurotech
13 October – 27 October 2026

Coherence Neuro raised a $45M Series A co-led by Founders Fund and the OpenAI Startup Fund. The company develops brain implants for glioblastoma, starting with CIPHER, a thin-film cortical probe first tested in three patients this summer. The funding will support its first long-term human trial, an FDA Breakthrough Device designation application, and preclinical research in pancreatic cancer.

#
4
Small Rounds, Big Results
23 June – 7 July 2026

Coherence Neuro placed its investigational cancer implant in three patients during brain tumor resection surgery at Royal Melbourne Hospital, marking the company's first in-human move. Led by Dr. Andrew Morokoff, who also performed Synchron's first implant, Coherence's trial will evaluate the cortical probe's ability to map and stimulate brain activity intraoperatively with high spatial resolution. Each placement lasted roughly 30 minutes. The data will be used for SOMA-1, Coherence's second-generation implant designed to sense and stimulate the tumor microenvironment as a longer-term therapeutic approach to brain cancer.

Articles featuring
Coherence Neuro